BioCryst Pharmaceuticals
BCRX
BCRX
233 hedge funds and large institutions have $1.24B invested in BioCryst Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 101 increasing their positions, 57 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
1% less funds holding
Funds holding: 236 → 233 (-3)
Holders
233
Holding in Top 10
6
Calls
$22.4M
Puts
$5.79M
Top Buyers
| 1 | +$18.2M | |
| 2 | +$13.9M | |
| 3 | +$11.2M | |
| 4 |
BlackRock
New York
|
+$9.05M |
| 5 |
Morgan Stanley
New York
|
+$6.77M |
Top Sellers
| 1 | -$29.9M | |
| 2 | -$12.7M | |
| 3 | -$8.82M | |
| 4 |
Fisher Asset Management
Camas,
Washington
|
-$8.07M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.85M |